A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004

Study identifier:D7260C00006

ClinicalTrials.gov identifier:NCT06742762

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Phase I, Multicentre, Single-Dose, Non-Randomised, Open-Label, Parallel Group Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004

Medical condition

Renal Impairment

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD5004

Sex

All

Estimated Enrollment

21

Study type

Interventional

Age

18 Years - 80 Years

Date

Study Start Date: 17 Dec 2024
Estimated Primary Completion Date: 23 Jun 2025
Estimated Study Completion Date: 23 Jun 2025

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2025 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria